<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538809</url>
  </required_header>
  <id_info>
    <org_study_id>2014-21</org_study_id>
    <nct_id>NCT02538809</nct_id>
  </id_info>
  <brief_title>Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals</brief_title>
  <official_title>Quantitative Evaluation of a Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Individuals With Symptoms or Clinical Findings Suspicious for Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Paraplegic Centre Nottwil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Paraplegic Centre Nottwil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer is a well-recognized complication in spinal cord injury (SCI) individuals. The&#xD;
      observed incidence rates in SCI individuals are considerably higher compared to the general&#xD;
      population. Bladder cancer in SCI individuals tends to present at an earlier age compared to&#xD;
      the general population. Furthermore, bladder cancer in SCI individuals is more commonly&#xD;
      invasive and at a more advanced stage at the time of diagnosis compared to bladder cancer in&#xD;
      the general population. Individuals with bladder cancer commonly present with hematuria and&#xD;
      other urinary symptoms. The gold standard for diagnosis is cystoscopy. However in SCI&#xD;
      individuals, hematuria may get attributed to catheter irritation or trauma or an urinary&#xD;
      tract infection. Furthermore, the bladder wall commonly presents with various changes under&#xD;
      cystoscopic examination masking the presence of a bladder wall mass. Thus, diagnosis of&#xD;
      bladder cancer in SCI individuals can be complicate.&#xD;
&#xD;
      There is a novel test available (GeneXpert® Bladder Cancer Detection, Cepheid International,&#xD;
      Sunnyvale, CA, USA) for the measurement of mRNA bladder tumor markers in the urine. The&#xD;
      diagnostic accuracy of this test has been investigated in non-SCI individuals with symptoms&#xD;
      suspicious for bladder cancer. The test showed high sensitivity and specificity values and is&#xD;
      thus a promising diagnostic or screening tool.. However, the diagnostic accuracy of the test&#xD;
      has not yet been investigated in SCI individuals.&#xD;
&#xD;
      The primary objective of the proposed study is to investigate whether urine mRNA tumor marker&#xD;
      levels in spinal cord injury individuals with symptoms and findings suspicious for bladder&#xD;
      cancer are a discriminator between individuals suffering from bladder cancer and those not&#xD;
      suffering from cancer.&#xD;
&#xD;
      Individuals presenting with symptoms suspicious of bladder cancer will undergo ultrasonic and&#xD;
      cystoscopic examination of the bladder. An urine sample will be taken, and the bladder will&#xD;
      be flushed for collecting a bladder fluid sample. In patients with bladder wall findings&#xD;
      suspicious of cancer, a bladder wall biopsy will be taken, according to clinical standard&#xD;
      practice. The bladder fluid and the bladder wall biopsy will be submitted for cytology and&#xD;
      histopathology examination, respectively. Tumor mRNA levels will be measured in the urine&#xD;
      sample.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>urine tumor mRNA concentration</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cystoscopic findings of bladder wall</measure>
    <time_frame>1 day</time_frame>
    <description>findings suspicious of bladder cancer present: yes / no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microscopic identification of cells in bladder fluid sample</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>histopathologic examination of the bladder wall biopsy</measure>
    <time_frame>1 day</time_frame>
    <description>diagnosis of bladder cancer: yes / no</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Spinal Cord Injury</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>measurement of tumor mRNA concentration in urine</intervention_name>
    <description>bed-side test of tumor mRNA concentration in urine</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        individuals presenting with symptoms or clinical findings suspicious for bladder cancer at&#xD;
        a tertiary urologic referral center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms suspicious of bladder cancer (haematuria, ultrasonic and cystoscopy findings)&#xD;
&#xD;
          -  Chronic spinal cord injury for a minimum of 3 years&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  History of bleeding disorder&#xD;
&#xD;
          -  Bladder augmentation&#xD;
&#xD;
          -  Acute, symptomatic urinary tract infection&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Urolithiasis&#xD;
&#xD;
          -  Previous intravesical treatment (e.g. bladder irrigation, botulinum toxin injection) &lt;&#xD;
             2 weeks)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Wöllner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schweizer Paraplegiker-Zentrum Nottwil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Wöllner</last_name>
    <phone>+41 41 939 59 41</phone>
    <email>jens.woellner@paraplegie.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Swiss Paraplegic Centre</name>
      <address>
        <city>Nottwil</city>
        <state>LU</state>
        <zip>CH-6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Woellner, MD</last_name>
      <phone>+41 41 939 59 41</phone>
      <email>jens.woellner@paraplegie.ch</email>
    </contact>
    <investigator>
      <last_name>Jens Woellner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

